Herceptin News and Research

RSS

Basal tumours may originate from breast stem cells that have undergone genetic mishaps

Findings support previous speculation that breast stem cells, or very early descendents, are the cells from which basal tumours arise.

24 Jul 2006

Herceptin-linked nanoparticles for targeted cancer therapy

Albumin nanoparticles have recently proven their mettle as anticancer agents with the 2005 approval of Abraxane to treat metastatic breast cancer.

17 Jul 2006

Trastuzumab results promising for HER-2 positive breast cancer patients

Researchers have shown that patients who receive trastuzumab at the same time as post-chemotherapy radiation treatments for HER-2 positive breast cancer have no more risk for major side effects or complications than those who do not receive the drug.

7 Jun 2006

HERA trial continues to demonstrate significant patient benefits from Herceptin

New 23-month follow-up data from HERA, one of the largest breast cancer trials ever carried out, show that Herceptin (trastuzumab) following standard chemotherapy significantly reduced the risk of death by 34% for women with early-stage HER2-positive breast cancer.

5 Jun 2006

"Smart bomb" cancer therapy combo effective

Experts have more good news on the breast cancer front; they say they by using a combination of therapies it may be possible to extend the lives of thousands of women with advanced breast cancer.

4 Jun 2006

Herceptin plus hormonal therapy holds breast cancer in check

Drug giant Roche believes it has proof that its cancer drug Herceptin when used in combination with hormonal therapy increases the time that some breast-cancer patients live without the cancer progressing.

29 May 2006

EU ruling on breast drug Herceptin will end 'post code lottery' in Britain

The European Union has approved the use of the breast cancer drug Herceptin for use in patients with an early stage of the aggressive HER2-positive type of breast cancer.

24 May 2006

Gene family of potential tumor inhibitors identified

Proteins from a newly discovered family of genes, LRIG, function as a retardant for a protein that is important to tumor cells. It is probably this mechanism that lends the gene family its inhibiting effect on cancer tumors.

17 May 2006

Gene amplification could guide treatment for high-risk breast cancer

A new study shows that breast cancer patients with an "amplification," or greater number of copies, of the TOP2A gene are 45% more likely than women who do not have this amplification to benefit from a longer course of anthracycline-based adjuvant chemotherapy.

11 May 2006

Australia's medicines regulator close to decision on herceptin

Australia's medicines regulator, the Therapeutic Goods Administration (TGA) is considering a recommendation by its expert committee, the Australian Drug Evaluation Committee (ADEC), to conditionally approve an application by Roche Products Pty Limited to extend the registration of the breast cancer drug Herceptin (trastuzumab) for use in HER2 positive localised breast cancer in addition to chemotherapy.

20 Apr 2006

Lack of response to herceptin may be reversed with PI3K inhibiting agents

Breast cancer patients with HER2-positive tumors who don't respond to Herceptin (trastuzumab) may benefit from cocktail therapy that includes Herceptin along with one or more PI3K inhibiting agents, say researchers at the University of Texas M. D. Anderson Cancer Center.

11 Apr 2006

Access to breast cancer wonder drug will depend on where you live

Access to a potentially life-saving breast cancer drug in the UK has nothing to do with need but rather where they happen to live.

10 Apr 2006

MIT look at how cells make life-or-death decisions

The biological processes underlying diseases such as rheumatoid arthritis and cancer are fundamentally linked, and should be linked in how they are treated with drugs, a series of MIT studies indicates.

6 Apr 2006

Call to speed access to innovative advances for all breast cancer patients

Breast cancer specialists and advocates at the 5th European Breast Cancer Conference (EBCC-5) called for patients to have equal and speedy access to new breast cancer treatments and procedures, as soon as they are validated by comparative clinical trials.

28 Mar 2006